Found 6 matching trials
Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria PHASE2 This study was designed to provide continued access to BCX9930 for particip...
Show More Location
Investigative Site
Learn More & Join Trial
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) PHASE2 The objective of this study was to determine the safety and therapeutic pot...
Show More Location
Investigative Site
Learn More & Join Trial
First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH PHASE1 This is a 3-part Phase 1 dose-ranging study to evaluate the safety, tolerab...
Show More Learn More & Join Trial
A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) PHASE2 This study was designed to evaluate the long-term safety of daily oral trea...
Show More Learn More & Join Trial
BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy PHASE2 The purpose of this study was to determine the efficacy and safety of BCX99...
Show More Location
Investigative Site
Learn More & Join Trial
BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy PHASE2 The purpose of this study was to determine the efficacy and safety of BCX99...
Show More Location
Investigative Site
Learn More & Join Trial